Source comparison
Best AOD-9604 Dosage Comparison: Research Contexts and Protocols
Acute lipolysis measurement (calorimetry studies) 250–500mcg Single dose Respiratory quotient shift, free fatty acid elevation within 90 minutes 1–3 days Ideal for mechanistic studies; single-dose design eliminates chronic adaptation variables Body composition
This comparison does not assign a generated winner or score.
- Acute lipolysis measurement (calorimetry studies)
- 250–500mcg
- Single dose
- Respiratory quotient shift, free fatty acid elevation within 90 minutes
- 1–3 days
- Ideal for mechanistic studies; single-dose design eliminates chronic adaptation variables
- Body composition research (DXA scan endpoints)
- 500mcg
- Once daily
- Fat mass reduction, lean mass preservation over time
- 12–16 weeks
- Standard clinical trial design; requires consistent fasted-state administration for reproducibility
- Comparative peptide studies (AOD-9604 vs other lipolytics)
- 300mcg
- Head-to-head efficacy, side effect profile comparison
- 8–12 weeks
- Lower dose reduces cost while maintaining statistical power for between-group differences
- Dose-response curve research
- 100mcg, 300mcg, 500mcg, 1mg
- Once daily (dose-stratified groups)
- Establish minimum effective dose and saturation point
- 4–8 weeks
- Critical for understanding therapeutic window; most institutions underdose in preliminary studies
- Long-term metabolic adaptation studies
- 250mcg
- Weight regain post-treatment, metabolic rate changes
- 24+ weeks (12 weeks treatment + 12 weeks washout)
- Lower dose mitigates receptor downregulation risk; washout period shows whether effects persist